Pharmacological treatment of benign prostatic hyperplasia

被引:8
作者
Oelke, M. [1 ]
Kuczyk, M. A. [1 ]
Herrmann, T. R. W. [1 ]
机构
[1] Hannover Med Sch, Klin Urol & Urol Onkol, D-30625 Hannover, Germany
来源
UROLOGE | 2009年 / 48卷 / 11期
关键词
Lower urinary tract symptoms; Benign prostatic hyperplasia; Benign prostatic obstruction; Pharmacological therapy; Disease progression; URINARY-TRACT SYMPTOMS; BLADDER OUTLET OBSTRUCTION; COMBINATION THERAPY; OVERACTIVE BLADDER; CONTINENCE SOCIETY; MEN; TOLTERODINE; AGE; DUTASTERIDE; PROGRESSION;
D O I
10.1007/s00120-009-2141-y
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The majority of men with benign prostatic hyperplasia (BPH) seek medical help because of lower urinary tract symptoms (LUTS). Pharmacological treatment of BPH is indicated if the patient has no absolute indications for prostate surgery or benign prostatic obstruction (BPO), but LUTS with a decrease of quality of life. Plant extracts can be prescribed in men with mild to moderate symptoms. alpha-Blockers can quickly and effectively decrease LUTS and symptomatic disease progression. If patients have predominantly bladder filling symptoms and a small prostate, muscarinic receptor antagonists are a viable treatment option. The combination of an a-blocker plus a muscarinic receptor antagonist is more effective than single drugs used alone. Especially in men with larger prostates, 5 alpha-reductase inhibitors can decrease LUTS and the probability of acute urinary retention as well as need for prostate surgery. The combination of alpha-blocker plus 5 alpha-reductase inhibitor can reduce LUTS and disease progression more effectively than single drugs.
引用
收藏
页码:1365 / 1375
页数:11
相关论文
共 19 条
[1]   Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction [J].
Abrams, P ;
Kaplan, S ;
Gans, HJD ;
Millard, R .
JOURNAL OF UROLOGY, 2006, 175 (03) :999-1004
[2]   NEW WORDS FOR OLD - LOWER URINARY-TRACT SYMPTOMS FOR PROSTATISM [J].
ABRAMS, P .
BRITISH MEDICAL JOURNAL, 1994, 308 (6934) :929-930
[3]  
Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
[4]   Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride [J].
Barkin, J ;
Guimaraes, M ;
Jacobi, G ;
Pushkar, D ;
Taylor, S ;
van Vierssen Trip, OB .
EUROPEAN UROLOGY, 2003, 44 (04) :461-466
[5]  
BERGES R, 2009, UROLOGE A IN PRESS
[6]   Male lower urinary tract symptoms and related health care seeking in Germany [J].
Berges, RR ;
Pientka, L ;
Höfner, K ;
Senge, T ;
Jonas, U .
EUROPEAN UROLOGY, 2001, 39 (06) :682-687
[7]   THE DEVELOPMENT OF HUMAN BENIGN PROSTATIC HYPERPLASIA WITH AGE [J].
BERRY, SJ ;
COFFEY, DS ;
WALSH, PC ;
EWING, LL .
JOURNAL OF UROLOGY, 1984, 132 (03) :474-479
[8]   SIMILARITY OF THE AMERICAN-UROLOGICAL-ASSOCIATION SYMPTOM INDEX AMONG MEN WITH BENIGN PROSTATE HYPERPLASIA (BPH), URETHRAL OBSTRUCTION NOT DUE TO BPH AND DETRUSOR HYPERREFLEXIA WITHOUT OUTLET OBSTRUCTION [J].
CHANCELLOR, MB ;
RIVAS, DA ;
KEELEY, FX ;
LOTFI, MA ;
GOMELLA, LG .
BRITISH JOURNAL OF UROLOGY, 1994, 74 (02) :200-203
[9]  
HALD T, 1989, PROSTATE, P69
[10]   Characteristics of patients presenting with LUTS/BPH in six European countries [J].
Hutchison, Annie ;
Farmer, Richard ;
Chapple, Christopher ;
Berges, Richard ;
Pientka, Ludger ;
Teillac, Pierre ;
Borkowski, Andrzej ;
Dobronski, Piotr .
EUROPEAN UROLOGY, 2006, 50 (03) :555-562